Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.330 -0.040 (-0.63%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Earnings Outlook For Emergent BioSolutions ↗

February 24, 2023

Via Benzinga

Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript ↗

November 08, 2022

EBS earnings call for the period ending September 30, 2022.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 16, 2023

Via Benzinga

Why Axcella Health Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket ↗

February 16, 2023

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares rose 54.1% to $0.9290 in pre-market trading after the company announced FDA clearance of its IND application to initiate a phase 2b/3 trial in the U.S....

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

February 16, 2023

It's time to start the day with an overview of the biggest pre-market stock movers worth keeping an eye on Thursday morning!

Via InvestorPlace

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

February 15, 2023

From Emergent BioSolutions

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 15, 2023

Via Benzinga

Monkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines ↗

February 15, 2023

Via Benzinga

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

February 15, 2023

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

February 06, 2023

From Emergent BioSolutions

Via GlobeNewswire

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

January 18, 2023

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

Via MarketBeat

Topics Stocks

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗

January 13, 2023

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

Via Benzinga

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

January 09, 2023

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

January 05, 2023

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

December 06, 2022

From Emergent BioSolutions

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

November 18, 2022

On Friday, 64 companies achieved new lows for the year.

Via Benzinga

EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023 ↗

November 15, 2022

SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3...

Via Benzinga

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals ↗

November 14, 2022

Via Benzinga

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

November 14, 2022

Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies

From Emergent BioSolutions

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 09, 2022

Gainers

Via Benzinga

'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target ↗

November 09, 2022

Via Benzinga

Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday ↗

November 10, 2022

Gainers

Via Benzinga

Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session ↗

November 09, 2022

Gainers

Via Benzinga

Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗

November 09, 2022

Biotech stocks were hammered Wednesday, including several that had good news.

Via Investor's Business Daily

MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday ↗

November 09, 2022

Via Benzinga

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

November 08, 2022

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

November 01, 2022

From Emergent BioSolutions

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.